Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0814 Mesoblast
BioCentury & Getty Images

Regulation

Cell therapy’s outlook brightens as Mesoblast clears ODAC hurdle

Aug 15, 2020 | 12:53 AM GMT

Mesoblast is looking ahead to Ryoncil’s Sept. 30 PDUFA date after ODAC panelists shrugged off FDA reviewers’ concerns over assays and backed approval of

Read the full 447 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE